One Health: EU agencies unite to tackle azole fungicide resistance in Aspergillus fungi

For the first time, the five EU health and environment agencies – EFSA, ECDC, ECHA, EEA and EMA[1]– supported by the JRC, reviewed how the use of azole substances outside human medicine affects public health.

Azole medicines are essential for treating aspergillosis, a serious infection caused by Aspergillus fungi. However, these fungi are increasingly becoming resistant to azole therapies, making treatment less effective.

Azole substances are widely used in plant protection products (‘pesticides’) to control fungal diseases in agriculture and horticulture, as veterinary medicines to treat fungal infections in animals, as biocides in wood preservatives, as industrial chemicals (e.g. intermediates and dyes), and in cosmetics (e.g. as anti-dandruff agents).

The joint report highlights that their broad use outside human medicine, particularly in agriculture, contributes to the risk of Aspergillus becoming azole-resistant. Exposure Concentration or amount of a particular substance that is taken in by an individual, population or ecosystem in a specific frequency over a certain amount of time to environments where azole fungicides are used, such as agricultural sites and woodwork, can potentially increase the risk of infection with azole-resistant Aspergillus spp.

Data collected from EU/EEA countries (2010–2021) and included in the report detail the use of azole fungicides across Europe. Plant protection products account for most of the reported sales across all sectors.